Supervisor：Ministry of Education of the People's Republic of ChinaSponsor：Sichuan University Editor-in-chief：LUO Fengming Publishing period：
Monthly
ISSN：1002-0179CN：51-1356/R
Citation：陳萍,張慶,周俊,唐偉林,李莎莎,胡義德. 西妥昔單抗聯合放射和化學療法治療晚期鼻咽癌患者的觀察與護理. West China Medical Journal, 2011, 26(5): 798-. doi: Copy
Copyright ? the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved
1.
Tham I, Lu J. Controversies and challenges in the current management of nasopharyngeal cancer[J]. Expert Rev Anticancer Ther, 2010, 10(9): 1439-1450.
2.
Le Tourneau C, Siu L. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck[J]. Curr Opin Oncol, 2008, 20(3): 256-263.
Pryor D, Porceddu S, Burmeister B, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer[J]. Radiother Oncol, 90(2): 172-176.
5.
Baselga J. The EGFR as a targe for anti-cancer therapy focus on cetuximab[J]. Eur J Cancer, 2001, 37(Suppl 4): 16-22.
6.
David E. Cetuximab in metastatic colorectal cancer[J]. London Cancer New Drugs Grorp-APC/DTC Briefing, 2005, 7(1): 1-10.
1. Tham I, Lu J. Controversies and challenges in the current management of nasopharyngeal cancer[J]. Expert Rev Anticancer Ther, 2010, 10(9): 1439-1450.
2. Le Tourneau C, Siu L. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck[J]. Curr Opin Oncol, 2008, 20(3): 256-263.
4. Pryor D, Porceddu S, Burmeister B, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer[J]. Radiother Oncol, 90(2): 172-176.
5. Baselga J. The EGFR as a targe for anti-cancer therapy focus on cetuximab[J]. Eur J Cancer, 2001, 37(Suppl 4): 16-22.
6. David E. Cetuximab in metastatic colorectal cancer[J]. London Cancer New Drugs Grorp-APC/DTC Briefing, 2005, 7(1): 1-10.
1/5
WeChat